BridgeBio stock jumps after rival heart drug fails key trial
Covered by 2 sources · 2 articles
2 outlets - including Yahoo and Thestreet - are covering this story. BridgeBio shares rallied after a rival ATTR-CM drug missed the main goal in a late-stage trial.
